Your article says the numbers cannot be questioned because they are published in the BMJ. But I’m confused by the conclusion of that cited publication, which reads thus:
“The safety profiles of SARS-CoV-2 vaccines in patients with I-RMD was reassuring and comparable with patients with NI-RMDs. The majority of patients tolerated their vacc…
Your article says the numbers cannot be questioned because they are published in the BMJ. But I’m confused by the conclusion of that cited publication, which reads thus:
“The safety profiles of SARS-CoV-2 vaccines in patients with I-RMD was reassuring and comparable with patients with NI-RMDs. The majority of patients tolerated their vaccination well with rare reports of I-RMD flare and very rare reports of serious AEs. These findings should provide reassurance to rheumatologists and vaccine recipients and promote confidence in SARS-CoV-2 vaccine safety in I-RMD patients.”
Your article says the numbers cannot be questioned because they are published in the BMJ. But I’m confused by the conclusion of that cited publication, which reads thus:
“The safety profiles of SARS-CoV-2 vaccines in patients with I-RMD was reassuring and comparable with patients with NI-RMDs. The majority of patients tolerated their vaccination well with rare reports of I-RMD flare and very rare reports of serious AEs. These findings should provide reassurance to rheumatologists and vaccine recipients and promote confidence in SARS-CoV-2 vaccine safety in I-RMD patients.”